Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
02/2012
02/23/2012US20120046351 Medicinal cannabis added in food
02/23/2012US20120046345 Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
02/23/2012US20120046344 Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
02/23/2012US20120046343 MULTI-TARGETING SHORT INTERFERING RNAs
02/23/2012US20120046336 Methods and compositions for improving cognitive function
02/23/2012US20120046330 Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d] [1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
02/23/2012US20120046329 Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof
02/23/2012US20120046325 Isoxazoline Compounds Having MIF Antagonist Activity
02/23/2012US20120046324 Small molecule inhibitors of kynurenine-3-monooxygenase
02/23/2012US20120046320 Beta- and gamma-diketones and gamma-hydroxyketones as wnt/beta-catenin signaling pathway activators
02/23/2012US20120046317 Novel heterocyclic compounds
02/23/2012US20120046312 3-substituted propanamine compounds
02/23/2012US20120046311 Chemokine receptor antagonists and methods of use thereof
02/23/2012US20120046309 Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
02/23/2012US20120046307 Allosteric protein kinase modulators
02/23/2012US20120046303 Benzimidazole poly(adp ribose)polymerase inhibitors
02/23/2012US20120046302 Methods of treating cns disorders
02/23/2012US20120046301 Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor
02/23/2012US20120046298 Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics
02/23/2012US20120046293 Renin inhibitors
02/23/2012US20120046289 Pyridazine Carboxamide Orexin Receptor Antagonists
02/23/2012US20120046286 Novel Compounds
02/23/2012US20120046283 Compounds for treating neuropsychiatric conditions
02/23/2012US20120046280 Novel heteropyrrole analogs acting on cannabinoid receptors
02/23/2012US20120046279 Oligomer-Phenothiazine Conjugates
02/23/2012US20120046277 Benzofuran derivatives
02/23/2012US20120046274 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
02/23/2012US20120046273 Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
02/23/2012US20120046272 Novel Therapeutic Compounds
02/23/2012US20120046271 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin
02/23/2012US20120046266 Resorcinol derivatives as hsp90 inhibitors
02/23/2012US20120046255 Non-steroidal compounds
02/23/2012US20120046243 Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators
02/23/2012US20120046239 Application of american ginseng to enhance neurocognitive function
02/23/2012US20120046232 Compositions and methods for reducing relapse of addictive behavior
02/23/2012US20120046229 Modified relaxin polypeptides and their uses
02/23/2012US20120046226 Combined Treatment of Multiple Sclerosis
02/23/2012US20120046219 Melanocortin receptor-specific peptides
02/23/2012US20120046218 Glycosaminoglycan-antagonising mcp-i mutants and methods of using same
02/23/2012US20120046217 TNF-alpha Antagonists Containing IGFBP5
02/23/2012US20120045528 Use of n20 gas for treating chronic pain
02/23/2012US20120045526 Pharmaceutical compound which includes clinoptilolite
02/23/2012US20120045512 Methods and substrates for differentiation of neural stem cells
02/23/2012US20120045508 Method and composition for administering an nmda receptor antagonist to a subject
02/23/2012US20120045506 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
02/23/2012US20120045503 Compositions And Methods For Wound Healing
02/23/2012US20120045500 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
02/23/2012US20120045499 Pearlescent pigment surface treatment for confectionery
02/23/2012US20120045483 Mannitol and/or Proline for Prevention and Treatment of Ageing Related Symptoms
02/23/2012US20120045462 Inflammation Inhibiting Compounds
02/23/2012US20120045459 Methods for Treating Autophagy-Related Disorders
02/23/2012US20120045452 Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM
02/23/2012US20120045451 Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM
02/23/2012US20120045444 Treatment for Neoplastic Diseases
02/23/2012US20120045443 Agonist anti-trk-c monoclonal antibodies
02/23/2012US20120045441 Methods of treating lung disease and other inflammatory diseases
02/23/2012US20120045438 Engineered anti-il-13 antibodies, compositions, methods and uses
02/23/2012US20120045435 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
02/23/2012US20120045430 Dendrimer-like modular delivery vector
02/23/2012US20120045419 Methods and uses of hypoxic compartment cells
02/23/2012DE102010034699A1 Pyrimidinderivate Pyrimidine derivatives
02/23/2012CA2809028A1 Nicotinic receptor compounds
02/23/2012CA2808660A1 Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
02/23/2012CA2808630A1 Methods of treating mild cognitive impairment (mci) and related disorders
02/23/2012CA2808372A1 Methods of generating oligodendrocytes and cell populations comprising same
02/23/2012CA2808307A1 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
02/23/2012CA2808210A1 Composition comprising tetracyclic compound
02/23/2012CA2808187A1 Amyloid-beta binding proteins
02/23/2012CA2807419A1 Diketones and hydroxyketones as catenin signaling pathway activators
02/23/2012CA2806634A1 Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
02/23/2012CA2804333A1 Nalbuphine-based formulations and uses thereof
02/22/2012EP2420572A1 Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof
02/22/2012EP2420569A1 Method for culturing bone marrow stromal cells and mesenchymal stem cells, and method for producing graft cells for treating central neurological disease
02/22/2012EP2420503A1 Process for the synthesis of 14-oxygenated morphinan-6-ones
02/22/2012EP2420501A1 Novel compound having 3-heteroarylpyrimidin-4-(3h)-one structure and pharmaceutical preparation containing same
02/22/2012EP2420496A2 Antiepileptic, hypocholesterolemic and neuroprotective compound
02/22/2012EP2420490A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
02/22/2012EP2420237A1 Fluorinated derivatives of endogenous isoquinolines for use in the treatment of diseases mediated through endogenous isoquinoline pathways
02/22/2012EP2420235A1 Methods and combination therapies for treating alzheimer's disease
02/22/2012EP2419447A1 Antibodies that specifically bind to a beta oligomers and use thereof
02/22/2012EP2419431A1 Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof
02/22/2012EP2419425A1 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
02/22/2012EP2419420A1 Indole derivative modulators of the alpha 7 nachr
02/22/2012EP2419405A1 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
02/22/2012EP2419400A1 Monoamine reuptake inhibitors
02/22/2012EP2419104A2 5-ht4 receptor agonist compounds for treatment of cognitive disorders
02/22/2012EP2419101A2 Method of treating disorders associated with protein kinase ck2 activity
02/22/2012EP2419100A2 Method of decreasing pro-adam10 secretase and/or beta secretase levels
02/22/2012EP2419097A1 Pharmaceutical compositions
02/22/2012EP2419094A1 Compounds for the treatment of mitochondrial diseases
02/22/2012EP2419093A2 Methods of reduction of interpatient variability
02/22/2012EP2300479B1 Nalmefene hydrochloride dihydrate
02/22/2012EP2099806B1 Spiropiperidine derivatives as nk3 antagonists
02/22/2012EP2076497B1 Aminomethyl-4-imidazoles
02/22/2012EP1805510B1 Therapeutic strategy for treating autoimmune and degenerative diseases
02/22/2012EP1799268B1 Magnetic particles for therapy and diagnosis
02/22/2012EP1786405B1 Use and compounds for perceiving or controlling alcool intake
02/22/2012EP1778637B1 FKBP-binding composition and pharmaceutical use thereof
02/22/2012EP1626049B1 Microcrystal of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione
02/22/2012EP1575531B9 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
1 ... 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 ... 1833